Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer
Year: 2026
Type: article
Source: Gynecologic Oncology
Authors: Emese Zsiros, Rutie Yin, Lucy Gilbert, Radosław Mądry, Pablo Rodriguez Monarca, Ram Eitan, Mayu Yunokawa, Fatih Kose, Yamil López Chuken, John McGrane, Andrew Dean, Nelleke Ottevanger, Andrea Juliana Gomes, Thaïs Baert, Eun Ji Nam, Agata Bogusz, Allison Martin Nguyen, Helen Ding, Thomas Jemielita, Laura Deiana, Nicoletta Colombo
Institutions: Roswell Park Comprehensive Cancer Center, Sichuan University, West China Second University Hospital of Sichuan University, McGill University Health Centre, Poznan University of Medical Sciences, Instituto de Radiomedicina, Rabin Medical Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Başkent University, Royal Cornwall Hospital, St John of God Subiaco Hospital, Radboud University Nijmegen, Radboud University Medical Center, Universitair Ziekenhuis Leuven, Yonsei University, Severance Hospital, Yonsei University Health System, Merck & Co., Inc., Rahway, NJ, USA (United States), European Institute of Oncology
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7155422382
FWCI:
Cites:
Cited by:
Related to: